Last reviewed · How we verify
ABT-288 High Dose
ABT-288 High Dose is a glucagon receptor antagonist.
ABT-288 High Dose is a glucagon receptor antagonist. Used for Type 2 diabetes.
At a glance
| Generic name | ABT-288 High Dose |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Glucagon receptor antagonists are a class of drugs that block the action of glucagon, a hormone that raises blood glucose levels. By blocking glucagon, ABT-288 High Dose is expected to lower blood glucose levels and improve glycemic control in patients with diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia (PHASE2)
- Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-288 High Dose CI brief — competitive landscape report
- ABT-288 High Dose updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI